Physician

Anthony F. Afong, M.D.

According to 2025 Medicare claims, Anthony Afong, M.D. (NPI: 1801864160) practices interventional pain management (ipm) in the Port St. Lucie, FL market, with the plurality of this provider's patient population coming from St. Lucie, FL. This provider's primary affiliated billing organization is FLORIDA PAIN AND REHABILITATION ASSOCIATES INC (NPI: 1053363457; TIN: 020599723) and primary practice location at 34986-3413. Afong is affiliated with the Sunflower ACO LLC (ACO ID: A5499) and Primary Care Alliance, LLC (ACO ID: D0010), participating under both the MSSP and REACH models.

Afong's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 223 traditional Medicare patients, billed 10,040 HCPCS/CPT codes, and received $176,001 in Medicare payments. The top billing code was G0482 (Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms). Part D data shows 3,893 prescription claims across 482 beneficiaries totaling $244,825 in drug costs, led by Xtampza Er (Oxycodone Myristate). 2021 DME data shows 11 claims. Open Payments data shows 81 records totaling $5,509. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $711,310 to $176,001. Similarly, Part D prescription costs have moved from a higher plateau to a lower plateau, from $653,078 to $244,825. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $1,691 and ending at $858.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	425	21,888	$711,310
2016	438	8,266	$505,434
2017	511	8,322	$625,227
2018	465	10,265	$665,189
2019	401	7,652	$517,553
2020	329	5,465	$436,445
2021	321	5,793	$463,925
2022	294	5,016	$292,427
2023	251	3,766	$164,986
2024	223	10,040	$176,001

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	443	4,115	$653,078
2016	432	4,041	$631,241
2017	486	4,244	$501,098
2018	440	3,927	$489,900
2019	428	3,458	$403,155
2020	417	3,971	$354,338
2021	445	4,477	$316,228
2022	505	4,547	$353,467
2023	510	4,305	$313,230
2024	482	3,893	$244,825

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	39	39	$39,862
2016	51	51	$50,453
2017	54	54	$54,977
2018	39	56	$39,923
2019	20	33	$21,928
2020	14	14	$15,246
2021	11	11	$11,813
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms	98	99	$195
62323	Injection of substance into lower spine canal using imaging guidance	57	67	$127
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	51	51	$115
99203	New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more	48	48	$80
80307	Testing for presence of drug, by chemistry analyzers	102	103	$61

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtampza Er	Oxycodone Myristate	118	3,420	$54,335
Nucynta Er	Tapentadol Hcl	21	630	$34,643
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	1,571	44,806	$26,301
Buprenorphine	Buprenorphine	57	1,596	$18,327
Nucynta	Tapentadol Hcl	24	720	$18,320

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	81	$5,509	Saluda Medical Americas, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Anthony F. Afong, M.D.?

Tedicare shows public-source Medicare data for Anthony F. Afong, M.D. (NPI 1801864160), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Anthony F. Afong, M.D. have ACO affiliation data?

Anthony F. Afong, M.D. is shown with ACO affiliation data for Sunflower ACO LLC (MSSP, ACO ID A5499) and Primary Care Alliance, LLC (REACH, ACO ID D0010).

What billing organization is linked to Anthony F. Afong, M.D.?

Anthony F. Afong, M.D. is linked to FLORIDA PAIN AND REHABILITATION ASSOCIATES INC (billing NPI 1053363457) in the available physician profile data.

Does Anthony F. Afong, M.D. have Open Payments data?

Anthony F. Afong, M.D. has 81 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.